Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPICE: Enadenotucirev + Nivolumab in Advanced Epithelial Tumors
NCT02636036Phase 1Completed
- Sponsor
- Akamis Bio
- Start
- Jan 2016
- Primary completion
- Oct 2021
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of enadenotucirev in Epithelial tumor, colorectal cancer (CRC), squamous cell carcinoma of the head and neck (HNSCC) and 3 more, sponsored by Akamis Bio. Primary endpoints: Incidence, nature and severity of adverse events at 12 months and Maximum Tolerated and/or Maximum Feasible Dose at 12 months. Started Jan 2016; status: completed.
02
Drugs
enadenotucirev
03
Conditions
Epithelial tumorcolorectal cancer (CRC)squamous cell carcinoma of the head and neck (HNSCC)urothelial carcinoma (UC)salivary gland cancer (SGC)
Beyond the preview
Go deeper on NCT02636036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02636036.